Molecular basis of estrogen regulation of Hageman factor XII gene expression

A. Farsetti, S. Misiti, F. Citarella, A. Felici, M. Andreoli, A. Fantoni, A. Sacchi, A. Pontecorvi

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Estrogen therapy has been reported to cause multiple alterations in hemostasis and to increase blood levels of several procoagulants, including Hageman factor [factor XII (FXII)]. Liver FXII gene expression has been investigated in ovariectomized rats, treated or not with 17β-estradiol. A 6- fold stimulation of FXII gene transcription was observed in treated compared to untreated animals, indicating that 17β-estradiol is able to induce FXII gene expression in vivo. We have recently shown that human FXII promoter contains an imperfect palindrome, 5'-GGGCAnnnTGACC-3', at position -43/-31 resembling the consensus estrogen-responsive element (ERE). Portions of different length of the FXII promoter were fused to the chloramphenicol acetyltransferase (CAT) coding sequence and transiently cotransfected with human estrogen receptor (ER) into NIH3T3 and HepG2 cells in the presence or absence of 17β-estradiol. A 230-base pair fragment of FXII promoter, spanning nucleotides -181/49, conferred a strong estrogen responsiveness to the CAT reporter gene, suggesting that a functional ERE resides in this region. Cognate receptors, such as those for thyroid hormone or retinoic acid, did not stimulate CAT activity. Gel mobility assays demonstrated a specific interaction between ER and the 230-bp FXII promoter fragment containing the putative ERE palindrome. Similar results were obtained when an oligonucleotide spanning the consensus ERE was used; the complex between ER and FXII promoter sequences was supershifted after the addition of an anti- er monoclonal antibody. Insertion of FXII-ERE into the heterologous thymidine kinase promoter conferred a strong estrogen responsiveness that was abolished by mutations of the 5'-half of the palindrome. These results represent the first demonstration at the molecular level of the regulation of a blood coagulation factor gene by 17β-estradiol as well as the first identification of a functional ERE within this class of genes.

Original languageEnglish
Pages (from-to)5076-5083
Number of pages8
JournalEndocrinology
Volume136
Issue number11
Publication statusPublished - 1995

Fingerprint

Factor XII
Estrogens
Gene Expression
Chloramphenicol O-Acetyltransferase
Estradiol
Estrogen Receptors
Genes
Blood Coagulation Factors
Thymidine Kinase
Hep G2 Cells
Tretinoin
Hemostasis
Thyroid Hormones
Reporter Genes
Oligonucleotides
Base Pairing
Nucleotides
Gels

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Farsetti, A., Misiti, S., Citarella, F., Felici, A., Andreoli, M., Fantoni, A., ... Pontecorvi, A. (1995). Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology, 136(11), 5076-5083.

Molecular basis of estrogen regulation of Hageman factor XII gene expression. / Farsetti, A.; Misiti, S.; Citarella, F.; Felici, A.; Andreoli, M.; Fantoni, A.; Sacchi, A.; Pontecorvi, A.

In: Endocrinology, Vol. 136, No. 11, 1995, p. 5076-5083.

Research output: Contribution to journalArticle

Farsetti, A, Misiti, S, Citarella, F, Felici, A, Andreoli, M, Fantoni, A, Sacchi, A & Pontecorvi, A 1995, 'Molecular basis of estrogen regulation of Hageman factor XII gene expression', Endocrinology, vol. 136, no. 11, pp. 5076-5083.
Farsetti A, Misiti S, Citarella F, Felici A, Andreoli M, Fantoni A et al. Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology. 1995;136(11):5076-5083.
Farsetti, A. ; Misiti, S. ; Citarella, F. ; Felici, A. ; Andreoli, M. ; Fantoni, A. ; Sacchi, A. ; Pontecorvi, A. / Molecular basis of estrogen regulation of Hageman factor XII gene expression. In: Endocrinology. 1995 ; Vol. 136, No. 11. pp. 5076-5083.
@article{a30bf8f774b14759aefb813bf9cd6d1c,
title = "Molecular basis of estrogen regulation of Hageman factor XII gene expression",
abstract = "Estrogen therapy has been reported to cause multiple alterations in hemostasis and to increase blood levels of several procoagulants, including Hageman factor [factor XII (FXII)]. Liver FXII gene expression has been investigated in ovariectomized rats, treated or not with 17β-estradiol. A 6- fold stimulation of FXII gene transcription was observed in treated compared to untreated animals, indicating that 17β-estradiol is able to induce FXII gene expression in vivo. We have recently shown that human FXII promoter contains an imperfect palindrome, 5'-GGGCAnnnTGACC-3', at position -43/-31 resembling the consensus estrogen-responsive element (ERE). Portions of different length of the FXII promoter were fused to the chloramphenicol acetyltransferase (CAT) coding sequence and transiently cotransfected with human estrogen receptor (ER) into NIH3T3 and HepG2 cells in the presence or absence of 17β-estradiol. A 230-base pair fragment of FXII promoter, spanning nucleotides -181/49, conferred a strong estrogen responsiveness to the CAT reporter gene, suggesting that a functional ERE resides in this region. Cognate receptors, such as those for thyroid hormone or retinoic acid, did not stimulate CAT activity. Gel mobility assays demonstrated a specific interaction between ER and the 230-bp FXII promoter fragment containing the putative ERE palindrome. Similar results were obtained when an oligonucleotide spanning the consensus ERE was used; the complex between ER and FXII promoter sequences was supershifted after the addition of an anti- er monoclonal antibody. Insertion of FXII-ERE into the heterologous thymidine kinase promoter conferred a strong estrogen responsiveness that was abolished by mutations of the 5'-half of the palindrome. These results represent the first demonstration at the molecular level of the regulation of a blood coagulation factor gene by 17β-estradiol as well as the first identification of a functional ERE within this class of genes.",
author = "A. Farsetti and S. Misiti and F. Citarella and A. Felici and M. Andreoli and A. Fantoni and A. Sacchi and A. Pontecorvi",
year = "1995",
language = "English",
volume = "136",
pages = "5076--5083",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - Molecular basis of estrogen regulation of Hageman factor XII gene expression

AU - Farsetti, A.

AU - Misiti, S.

AU - Citarella, F.

AU - Felici, A.

AU - Andreoli, M.

AU - Fantoni, A.

AU - Sacchi, A.

AU - Pontecorvi, A.

PY - 1995

Y1 - 1995

N2 - Estrogen therapy has been reported to cause multiple alterations in hemostasis and to increase blood levels of several procoagulants, including Hageman factor [factor XII (FXII)]. Liver FXII gene expression has been investigated in ovariectomized rats, treated or not with 17β-estradiol. A 6- fold stimulation of FXII gene transcription was observed in treated compared to untreated animals, indicating that 17β-estradiol is able to induce FXII gene expression in vivo. We have recently shown that human FXII promoter contains an imperfect palindrome, 5'-GGGCAnnnTGACC-3', at position -43/-31 resembling the consensus estrogen-responsive element (ERE). Portions of different length of the FXII promoter were fused to the chloramphenicol acetyltransferase (CAT) coding sequence and transiently cotransfected with human estrogen receptor (ER) into NIH3T3 and HepG2 cells in the presence or absence of 17β-estradiol. A 230-base pair fragment of FXII promoter, spanning nucleotides -181/49, conferred a strong estrogen responsiveness to the CAT reporter gene, suggesting that a functional ERE resides in this region. Cognate receptors, such as those for thyroid hormone or retinoic acid, did not stimulate CAT activity. Gel mobility assays demonstrated a specific interaction between ER and the 230-bp FXII promoter fragment containing the putative ERE palindrome. Similar results were obtained when an oligonucleotide spanning the consensus ERE was used; the complex between ER and FXII promoter sequences was supershifted after the addition of an anti- er monoclonal antibody. Insertion of FXII-ERE into the heterologous thymidine kinase promoter conferred a strong estrogen responsiveness that was abolished by mutations of the 5'-half of the palindrome. These results represent the first demonstration at the molecular level of the regulation of a blood coagulation factor gene by 17β-estradiol as well as the first identification of a functional ERE within this class of genes.

AB - Estrogen therapy has been reported to cause multiple alterations in hemostasis and to increase blood levels of several procoagulants, including Hageman factor [factor XII (FXII)]. Liver FXII gene expression has been investigated in ovariectomized rats, treated or not with 17β-estradiol. A 6- fold stimulation of FXII gene transcription was observed in treated compared to untreated animals, indicating that 17β-estradiol is able to induce FXII gene expression in vivo. We have recently shown that human FXII promoter contains an imperfect palindrome, 5'-GGGCAnnnTGACC-3', at position -43/-31 resembling the consensus estrogen-responsive element (ERE). Portions of different length of the FXII promoter were fused to the chloramphenicol acetyltransferase (CAT) coding sequence and transiently cotransfected with human estrogen receptor (ER) into NIH3T3 and HepG2 cells in the presence or absence of 17β-estradiol. A 230-base pair fragment of FXII promoter, spanning nucleotides -181/49, conferred a strong estrogen responsiveness to the CAT reporter gene, suggesting that a functional ERE resides in this region. Cognate receptors, such as those for thyroid hormone or retinoic acid, did not stimulate CAT activity. Gel mobility assays demonstrated a specific interaction between ER and the 230-bp FXII promoter fragment containing the putative ERE palindrome. Similar results were obtained when an oligonucleotide spanning the consensus ERE was used; the complex between ER and FXII promoter sequences was supershifted after the addition of an anti- er monoclonal antibody. Insertion of FXII-ERE into the heterologous thymidine kinase promoter conferred a strong estrogen responsiveness that was abolished by mutations of the 5'-half of the palindrome. These results represent the first demonstration at the molecular level of the regulation of a blood coagulation factor gene by 17β-estradiol as well as the first identification of a functional ERE within this class of genes.

UR - http://www.scopus.com/inward/record.url?scp=0028827650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028827650&partnerID=8YFLogxK

M3 - Article

C2 - 7588244

AN - SCOPUS:0028827650

VL - 136

SP - 5076

EP - 5083

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 11

ER -